AR047803A1 - LIQUID AND SOLID COMPOSITIONS THAT INCLUDE A PRODUCTION OF A PROTON PUMP INHIBITOR, SUCH COMPOSITIONS UNDERSTANDING A SECOND THERAPEUTICALLY EFFECTIVE AGENT AND USE OF A PROTON PUMP INHIBITOR FOR THE PREPARATION OF LIQUID COMPOSITIONS - Google Patents

LIQUID AND SOLID COMPOSITIONS THAT INCLUDE A PRODUCTION OF A PROTON PUMP INHIBITOR, SUCH COMPOSITIONS UNDERSTANDING A SECOND THERAPEUTICALLY EFFECTIVE AGENT AND USE OF A PROTON PUMP INHIBITOR FOR THE PREPARATION OF LIQUID COMPOSITIONS

Info

Publication number
AR047803A1
AR047803A1 ARP050100546A ARP050100546A AR047803A1 AR 047803 A1 AR047803 A1 AR 047803A1 AR P050100546 A ARP050100546 A AR P050100546A AR P050100546 A ARP050100546 A AR P050100546A AR 047803 A1 AR047803 A1 AR 047803A1
Authority
AR
Argentina
Prior art keywords
proton pump
pump inhibitor
compositions
liquid
composition
Prior art date
Application number
ARP050100546A
Other languages
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR047803A1 publication Critical patent/AR047803A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Composicion que comprende una prodroga N-fenilsulfonilo de un inhibidor de la bomba de proton que comprende una fraccion solubilizante, disuelta en un líquido acuoso que tiene un pH de desde 3 a 7,3. Dicha fraccion de solubilizante comprende un grupo funcional ácido, o una sal farmacéuticamente aceptable de las mismas. Preferentemente, la composicion comprende el compuesto de formula (1), o una sal farmacéuticamente aceptable de las mismas, donde, A es H, OCH3, o OCHF2; B es CH3 o OCH3; D es OCH3, PCH2CF3, o O(CH2)3OCH3; E es H o CH3; R1, R2, R3 y R5 son independientemente H, CH3, CO2H, CH2CO2H, (CH2)2CO2H; CH(CH3)2, OCH2C(CH3)2CO2H, OCH2CO2CH3, OCH2CO2H, OCH2CO2NH2, OCH2CONH2(CH2)5CO2CH3, o OCH3, con la condicion de que al menos uno de R1, R2, R3 y R5 comprenda un grupo funcional del ácido carboxílico. Dicha composicion puede comprender además un segundo agente terapéuticamente efectivo. Uso de un inhibidor de la bomba de proton para preparar una solucion acuosa de la composicion descripta, util para administrar parenteralmente dicho inhibidor de la bomba de proton a un mamífero, en donde dicha solucion acuosa tiene un pH que es mayor que o igual a 3 y menos que 7. composicion solida que comprende una prodroga de un inhibidor de la bomba de proton que comprende una fraccion sulfonilo y un ácido carboxílico, o una sal farmacéuticamente aceptable de las mismas; y composicion solida que comprende una sulfonamida de un inhibidor de la bomba de proton y un segundo agente terapéuticamente efectivo.Composition comprising an N-phenylsulfonyl prodrug of a proton pump inhibitor comprising a solubilizing fraction, dissolved in an aqueous liquid having a pH of from 3 to 7.3. Said solubilizer fraction comprises an acid functional group, or a pharmaceutically acceptable salt thereof. Preferably, the composition comprises the compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein, A is H, OCH3, or OCHF2; B is CH3 or OCH3; D is OCH3, PCH2CF3, or O (CH2) 3OCH3; E is H or CH3; R1, R2, R3 and R5 are independently H, CH3, CO2H, CH2CO2H, (CH2) 2CO2H; CH (CH3) 2, OCH2C (CH3) 2CO2H, OCH2CO2CH3, OCH2CO2H, OCH2CO2NH2, OCH2CONH2 (CH2) 5CO2CH3, or OCH3, with the proviso that at least one of R1, R2, R3 and R5 comprises a carboxylic acid functional group . Said composition may further comprise a second therapeutically effective agent. Use of a proton pump inhibitor to prepare an aqueous solution of the described composition, useful for parenterally administering said proton pump inhibitor to a mammal, wherein said aqueous solution has a pH that is greater than or equal to 3 and less than 7. solid composition comprising a prodrug of a proton pump inhibitor comprising a sulfonyl fraction and a carboxylic acid, or a pharmaceutically acceptable salt thereof; and solid composition comprising a sulfonamide of a proton pump inhibitor and a second therapeutically effective agent.

ARP050100546A 2004-02-18 2005-02-16 LIQUID AND SOLID COMPOSITIONS THAT INCLUDE A PRODUCTION OF A PROTON PUMP INHIBITOR, SUCH COMPOSITIONS UNDERSTANDING A SECOND THERAPEUTICALLY EFFECTIVE AGENT AND USE OF A PROTON PUMP INHIBITOR FOR THE PREPARATION OF LIQUID COMPOSITIONS AR047803A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54580904P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
AR047803A1 true AR047803A1 (en) 2006-02-22

Family

ID=34910732

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100546A AR047803A1 (en) 2004-02-18 2005-02-16 LIQUID AND SOLID COMPOSITIONS THAT INCLUDE A PRODUCTION OF A PROTON PUMP INHIBITOR, SUCH COMPOSITIONS UNDERSTANDING A SECOND THERAPEUTICALLY EFFECTIVE AGENT AND USE OF A PROTON PUMP INHIBITOR FOR THE PREPARATION OF LIQUID COMPOSITIONS

Country Status (9)

Country Link
US (2) US20070161679A1 (en)
EP (1) EP1715854A2 (en)
JP (1) JP2007523164A (en)
AR (1) AR047803A1 (en)
AU (1) AU2005216863A1 (en)
BR (1) BRPI0507837A (en)
CA (1) CA2557471A1 (en)
TW (1) TW200536538A (en)
WO (1) WO2005082338A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265311A1 (en) * 2006-01-10 2007-11-15 Rubino Mark P Therapeutic Salt Compositions and Methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (en) * 1974-05-16 1981-01-26 Haessle Ab PROCEDURE FOR THE PREPARATION OF SUBSTANCES WHICH PREVENT Gastric acid secretion
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (en) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (en) * 1985-10-29 1985-10-29 Haessle Ab NOVEL PHARMACOLOGICAL COMPOUNDS
FI90544C (en) * 1986-11-13 1994-02-25 Eisai Co Ltd Process for Preparation as Drug Useful 2-Pyridin-2-yl-methylthio- and sulfinyl-1H-benzimidazole derivatives
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
CA2083606C (en) * 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE510650C2 (en) * 1997-05-30 1999-06-14 Astra Ab New association
DE69905171T2 (en) * 1998-08-10 2003-11-20 Winston Pharmaceuticals Llc Ne PRODRUGS FOR PROTON PUMP INHIBITORS
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
KR100788778B1 (en) * 2002-07-19 2007-12-27 윈스턴 파마슈티컬즈, 엘엘씨 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
NZ544173A (en) * 2003-07-15 2009-04-30 Alevium Pharmaceuticals Inc Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
JP2007523163A (en) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド Methods and compositions for the administration of prodrugs of proton pump inhibitors
US20070265311A1 (en) * 2006-01-10 2007-11-15 Rubino Mark P Therapeutic Salt Compositions and Methods
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
US20070293543A1 (en) * 2006-06-19 2007-12-20 Edward Lee THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z

Also Published As

Publication number Publication date
AU2005216863A1 (en) 2005-09-09
EP1715854A2 (en) 2006-11-02
TW200536538A (en) 2005-11-16
US20070161679A1 (en) 2007-07-12
BRPI0507837A (en) 2007-07-10
CA2557471A1 (en) 2005-09-09
US20100222390A1 (en) 2010-09-02
JP2007523164A (en) 2007-08-16
WO2005082338A3 (en) 2006-10-26
WO2005082338A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
AR035710A1 (en) COMPOSITE DERIVED FROM BETA-CYCLINE AMINO ACIDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A DISEASE MEDIAATED BY MMPS, TNF, AGRECANASA AND COMBINATIONS OF THE SAME
ES2215893T3 (en) DERIVATIVES OF BETA-AMINO ACIDS AS INHIBITORS OF METALOPROTEASES OF MATRIX AND TNF-ALFA.
ES2572980T3 (en) Combination of HCV protease inhibitors with a surfactant
ECSP055815A (en) COMPOSITION FOR THE TREATMENT OF INFECTION BY VIRUS FLAVIVIRIDAE
UY27320A1 (en) NEW PHARMACEUTICAL COMPOSITIONS
AR069490A1 (en) GLUCOCORTICOID RECEPTORS AGONISTS
PE20081493A1 (en) NEW DERIVATIVES OF 1,4-BENZOTHYPE-1,1-DIOXIDE SUBSTITUTED WITH BENZYL RADICALS, METHOD FOR THEIR PREPARATION, PHARMACEUTICAL PRODUCTS INCLUDING THESE COMPOUNDS AND THEIR USE
PE20080331A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS INCLUDING FESOTERODINE
PE20060003A1 (en) POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING
AR047081A1 (en) DERIVATIVES OF PROSTAGLANDINAS, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION.
PE20080123A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VX-950 IN THE TREATMENT OF HEPATITIS C
AR087301A1 (en) CARBOXAMIDE AND UREA DERIVATIVES CONTAINING HITEROAROMATIC PIRAZOL REPLACED AS VANILLOID RECEIVER LIGANDS
BR0108893B1 (en) pharmaceutical composition containing azetidine derivatives, azetidine derivative compound, and process for the preparation of compounds.
AR060220A1 (en) HETEROCICLICAL COMPOUNDS OF 5 OR 6 MEMBERS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DGAT1.
PE20050772A1 (en) PIPERIDINYLCARBONYL-PYRROLIDINES AS MELANOCORTINE AGONISTS
AR050463A1 (en) ANALAGOS OF LONIDAMINE AND ITS USE IN MALE ANTI-CONCEPTION AND IN THE TREATMENT AGAINST CANCER.
CO6220840A2 (en) FORMULATIONS FOR CANCER TREATMENT
AR054129A1 (en) DERIVATIVES OF 2, 6-QUINOLINILO, A PHARMACEUTICAL PREPARATION THAT CONTAINS THEM AND ITS EMPLOYMENT IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DEPENDENT DISEASES OF INTEGRINES ALFA4BETA1 AND / OR ALFA4BETA7
AR061134A1 (en) THIOXANTINE DERIVATIVES
ECSP077402A (en) DERIVATIVES OF 2-AMIDO-4-PHENYLTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
EA200702384A1 (en) TREATMENT OF DISEASES OF THE LIVER, IN PATHOGENESIS OF WHICH IS IRINED
PE20220704A1 (en) 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PROAPOPTOTIC AGENTS
NO20025999D0 (en) Clear, aqueous anesthetic
AR082049A1 (en) LIQUID FORMULATIONS OF RUPATADINA FUMARATO
PE20070120A1 (en) DERIVATIVES OF PROSTAGLANDIN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal